Charles River Associates (CRA) Expands Its Life Sciences Practice

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. ROST
2. WMT
3. AAP
4. SFNC
5. FMG:AU

6. AVAH
7. JHX
8. FSUGY
9. ANF
10. HD

Get Alerts CRAI Hot Sheet

Price: $174.38 --0%

Overall Analyst Rating:
SELL (= Flat)

Dividend Yield: 1.3%

Join SI Premium – FREE

BOSTON--(BUSINESS WIRE)-- Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that Ayushman Ghosh has joined the company’s Life Sciences Practice as a vice president.

“Ayushman has deep expertise in advising life sciences clients on commercial, clinical, medical, and manufacturing strategy in the gene therapy, rare disease, and oncology spaces,” said Paul Maleh, CRA’s Chairman and Chief Executive Officer. “I am pleased to welcome him to CRA, where he is joining a team that has long been recognized for its ability to provide clarity and solutions for the industry’s most complex issues.”

“Ayushman has the perspective of both an industry veteran and an experienced consultant, which is an invaluable asset in working with life sciences companies, particularly in helping them to develop and implement commercialization and product launch strategies,” said Dr. Gregory K. Bell, Group Vice President and Life Sciences Practice Leader.

Prior to joining CRA, Ghosh led several practice areas, key partnerships, and biotech investments as a senior vice president for a life sciences-focused boutique consulting firm. He led a team of more than 20 consultants across major accounts and alliance partnerships with a focus on gene therapy, rare disease, and oncology. Previously, he drove commercial, market access, and corporate strategy engagements at a management consulting firm specializing in the biopharmaceutical industry. He started his career as a scientist at a large, multinational pharmaceutical company where he focused on process optimization and commercialization of novel biologics. Ghosh has a MS in Chemical Engineering from Columbia University and a BS in Chemical Biological Engineering from the Massachusetts Institute of Technology.

About CRA’s Life Sciences Practice

The CRA Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of Ayushman Ghosh, CRA’s Life Sciences Practice, the expansion of the Life Sciences Practice, and any future business Mr. Ghosh may generate for CRA, are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.